Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

NewAmsterdam Pharma · with Midwest Biomedical Research · NCT06982508

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2
Target enrollment
100
US sites recruiting
1
Study start
September 9, 2025
Record last updated
October 20, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:

Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.

Participants will

Take Obicetrapib or a placebo every day for 4 months Visit the clinic once every 8 weeks for checkups and tests Have their blood taken and their eyes checked to measure antioxidant levels

Being studied: Obicetrapib 10mg; Placebo

Conditions: Antioxidant Absorption

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Visual acuity > 20/60 in both eyes with or without corrective lenses

Exclusion Criteria

  • Type 2 diabetes
  • Active liver disease
  • Any clinically significant macular pathology

Recruiting US locations

  • Excellence Medical Research

    Miami Gardens, FL 33169

    Site contact: Denis Ruiz · 786-320-5229 · druiz@emrclinic.com

All healthy volunteers studies in Florida →
Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL… (NCT06982508) | Bored Studies